Europe's CHMP recommends 10 drugs in 1 week

It was a very, very big week in Europe for drugmakers. The European Committee for Medicinal Products for Human Use (CHMP) recommended 10 drugs for approval, including two biosimilars, it said today. It gave the nod to three medicines to treat cancer, including  Provenge from Dendreon ($DNDN), Bayer's Stivarga and GlaxoSmithKline's ($GSK) Tafinlar. There was also a positive recommendation for Sanofi's ($SNY) Lemtrada for some patients with multiple sclerosis. The biosimilars go up against the blockbuster rheumatoid arthritis drug Remicade from Johnson & Johnson ($JNJ) and Merck & Co. ($MRK). The biosimilars are Remsima, made by South Korea's Celltrion, and Inflectra, which comes from Hospira ($HSP). Drugmakers are watching the biosimilar market in Europe very closely for ideas of how it will play out in the U.S. when the rules are finally set here. Release | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.